{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:36:58Z","timestamp":1787243818167,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Renal cell carcinoma (RCC) is a leading cause of mortality among genitourinary malignancies with limited therapeutic options. The hematogenous route, lymphatic spread, and direct invasion have been documented in RCC. Usually, metastases are regional lymph nodes, lungs, bone, liver, adrenal glands, contralateral kidney, and brain. Metastases to the rare sites such as skin, breast, head and neck were documented in the literature. In the present case, we describe the synchronous metastases to the base of the tongue and thyroid gland in RCC and the response to sunitinib therapy on\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000005152","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T15:01:19Z","timestamp":1712242879000},"page":"e208-e210","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["FDG PET\/CT in the Diagnosis and After Sunitinib Follow-up of Synchronous Base of Tongue and Thyroid Metastases From Renal Cell Carcinoma"],"prefix":"10.1097","volume":"49","author":[{"given":"Srinivas Ananth","family":"Kumar","sequence":"first","affiliation":[{"name":"Nuclear Medicine and PET\/CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwant Rai","family":"Mittal","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET\/CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET\/CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmandeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET\/CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajender","family":"Kumar","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET\/CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanjit","family":"Bal","sequence":"additional","affiliation":[{"name":"Pathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20250621","first-page":"201","article-title":"The place of FDG PET\/CT in renal cell carcinoma: value and limitations","volume":"6","year":"2016","journal-title":"Front Oncol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2019 update","volume":"75","year":"2019","journal-title":"Eur Urol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/cncr.24685","article-title":"Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis","volume":"116","year":"2010","journal-title":"Cancer"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/bjc.2011.103","article-title":"Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial","volume":"104","year":"2011","journal-title":"Br J Cancer"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4236\/jct.2017.86051","article-title":"Cutaneous metastasis of renal cell carcinoma: a case report","volume":"8","year":"2017","journal-title":"J Cancer Ther"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/1752-1947-2-313","article-title":"Oral cavity metastasis of renal cell carcinoma: a case report","volume":"2","year":"2008","journal-title":"J Med Case Reports"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/1752-1947-2-249","article-title":"Tongue metastasis as an initial presentation of renal cell carcinoma: a case report and literature review","volume":"2","year":"2008","journal-title":"J Med Case Reports"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1089\/thy.2010.0154","article-title":"Metastases to the thyroid: a review of the literature from the last decade","volume":"22","year":"2012","journal-title":"Thyroid"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T15:04:56Z","timestamp":1750518296000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005152","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}